Restoration of natural killer cell cytotoxicity in the suppressive tumor microenvironment: novel approaches to treat AML

Restoration of natural killer cell cytotoxicity in the suppressive tumor microenvironment: novel... Acute myeloid leukemia (AML) is a hematologic malignancy that is not completely cured in patients even after heavy chemotherapy treatments, resulting in the relapses of disease. Inactivation of immune cells such as natural killer (NK) cells is probably one of the causes of relapse. In this review, we described the role of NK cells in AML patients and outlined the current approaches to use of these cells in treatment of AML disease. Relevant articles from 1997 up to date, published in PubMed, were studied and compiled. The articles all contained the keywords: natural killer cell, acute myeloid leukemia, and treatment. Recognition of AML blast cells by NK inhibitory receptors and their interaction reduces NK cell cytotoxicity. On the other hand, NK cell immunotherapy along with administration of cytokines such as IL-2 and IL-15 can enhance the expression of activating receptors such as NKG2D and reduce the incidence of relapse in AML patients. Targeting NK inhibitory receptors and the use of IL-2 and IL-15 cytokine therapy can upregulate NK-activating receptors which decrease the relapse rate and improve the survival of patients with AML. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Hematopathology Springer Journals

Restoration of natural killer cell cytotoxicity in the suppressive tumor microenvironment: novel approaches to treat AML

Loading next page...
 
/lp/springer_journal/restoration-of-natural-killer-cell-cytotoxicity-in-the-suppressive-GRAuqSSjjU
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag GmbH Germany
Subject
Medicine & Public Health; Pathology; Hematology
ISSN
1868-9256
eISSN
1865-5785
D.O.I.
10.1007/s12308-017-0306-y
Publisher site
See Article on Publisher Site

Abstract

Acute myeloid leukemia (AML) is a hematologic malignancy that is not completely cured in patients even after heavy chemotherapy treatments, resulting in the relapses of disease. Inactivation of immune cells such as natural killer (NK) cells is probably one of the causes of relapse. In this review, we described the role of NK cells in AML patients and outlined the current approaches to use of these cells in treatment of AML disease. Relevant articles from 1997 up to date, published in PubMed, were studied and compiled. The articles all contained the keywords: natural killer cell, acute myeloid leukemia, and treatment. Recognition of AML blast cells by NK inhibitory receptors and their interaction reduces NK cell cytotoxicity. On the other hand, NK cell immunotherapy along with administration of cytokines such as IL-2 and IL-15 can enhance the expression of activating receptors such as NKG2D and reduce the incidence of relapse in AML patients. Targeting NK inhibitory receptors and the use of IL-2 and IL-15 cytokine therapy can upregulate NK-activating receptors which decrease the relapse rate and improve the survival of patients with AML.

Journal

Journal of HematopathologySpringer Journals

Published: Oct 11, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off